

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 November 2019 (21.11.2019)



(10) International Publication Number
WO 2019/222272 A1

(51) International Patent Classification:

A61K 45/06 (2006.01) C07D 401/14 (2006.01)

A61K 47/48 (2006.01)

(21) International Application Number:

PCT/US2019/032295

(22) International Filing Date:

14 May 2019 (14.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/671,382 14 May 2018 (14.05.2018) US

(71) Applicant: **NUVATION BIO INC.** [US/US]; c/o Sheppard Mullin Richter & Hampton LLP, Four Embarcadero Center, Suite 1700, San Francisco, California 94111 (US).

(72) Inventors: **PHAM, Son Minh**; c/o SparcBio LLC, P.O. Box 318009, San Francisco, California 94131 (US). **CHAKRAVARTY, Sarvajit**; c/o SparcBio LLC, P.O. Box 318009, San Francisco, California 94131 (US). **CHEN, Jiyun**; c/o SparcBio LLC, P.O. Box 318009, San Francisco, California 94131 (US). **KANKANALA, Jayakanth**; c/o SparcBio LLC, P.O. Box 318009, San Francisco, California 94131 (US). **BARDE, Anup**; c/o Intergral BioSciences, PVT. LTD., C-64 Hosiery Complex, Phase II, Noida, Uttar Pradesh 201306 (IN). **NAYAK, Anjan Kumar**; c/o Intergral BioSciences, PVT. LTD., C-64 Hosiery Complex, Phase II, Noida, Uttar Pradesh 201306 (IN). **HUNG, David**; c/o Sheppard Mullin Richter & Hampton LLP, Four Embarcadero Center, 17th Floor, San Francisco, California 94111 (US).

(74) Agent: **TANNER, Lorna L.** et al.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

WO 2019/222272 A1

(54) Title: ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

(57) Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.